TALVEY Drug Gets Extra Patent Life from FDA
Published Date: 6/20/2025
Notice
Summary
The FDA has officially set the review period for TALVEY, a human biological product, so its patent can be extended. This helps the company get extra time to protect their invention after the long approval process. If you’re involved in patents or drug development, this means the clock is ticking on TALVEY’s patent life and potential market exclusivity.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
TALVEY Patent Extension Eligible
The FDA has determined the regulatory review period for TALVEY, a human biological product, and published that determination. That allows the patent holder to apply to the U.S. Patent and Trademark Office for an extension of a patent claiming TALVEY so the company can seek extra time to protect the product after approval.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in